2026-W46 · Nov 9–Nov 15 · Company · Profile · published
DaVita Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #480 · 達維塔公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | DVA |
| Company | DaVita Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Services |
| S&P 500 rank (by weight) | #480 · 0.02% (Nov 5, 2026) |
| Sector rank | #55 of 60 in Health Care (Nov 5, 2026) |
| Headquarters | Denver, Colorado, United States |
| Founded | 1979 |
| CEO | Javier J. Rodriguez (Chief Executive Officer) |
| Employees | ~78,000 (as of December 31, 2025) |
| Market cap | $11.94B (Nov 5, 2026) |
| SEC filings | EDGAR — CIK 927066 |
WHAT IT DOES
DaVita Inc. is one of the largest kidney care companies in the United States. Its core U.S. dialysis business treats patients with chronic kidney failure and end-stage kidney disease (ESKD), who typically need dialysis three times a week unless they receive a transplant. At December 31, 2025 it operated 2,657 outpatient dialysis centers in the U.S. serving approximately 200,500 patients, provided inpatient dialysis services in hospitals, and ran related clinical laboratories; outside the U.S. it operated dialysis centers in 14 other countries serving about 94,500 patients, as described in its Form 10-K reporting. DaVita is paid mainly by health insurers rather than by patients directly. Government programs dominate volume — about 89% of its U.S. patients were covered by government-based insurance in 2025 and about 68% of U.S. dialysis patient service revenues came from Medicare and other government programs — while commercial insurers, covering a minority of patients, reimburse at much higher rates and generate nearly all of the profit. Around this core, its ancillary segment adds integrated kidney care, disease management, clinical research, physician services and transplant software, aiming to manage patients earlier in the course of kidney disease.
BUSINESS SEGMENTS
| U.S. Dialysis | Kidney dialysis services for patients with chronic kidney failure and end-stage kidney disease through 2,657 U.S. outpatient dialysis centers serving approximately 200,500 patients at December 31, 2025, plus inpatient dialysis in hospitals and related laboratory services. Total segment revenues were $11,792.9M in FY2025, including $61.0M of intersegment revenues. |
| Other — Ancillary Services | Ancillary and integrated kidney-care services, including international dialysis operations, integrated care and disease-management programs for kidney patients, clinical research, physician services and transplant-related software (MedSleuth). Total segment revenues were $1,922.3M in FY2025, including $11.2M of intersegment revenues. |
HISTORY
| Year | Milestone |
|---|---|
| 1979 | The business was founded as Medical Ambulatory Care, Inc., a subsidiary of National Medical Enterprises (now Tenet Healthcare), the origin DaVita traces its history to. |
| 1994 | DLJ Merchant Banking Partners acquired 70% of the company in a $75.5 million leveraged buyout; it was renamed Total Renal Care Holdings, Inc. and went public in an October 1995 IPO. |
| 1999 | After a difficult integration of Renal Treatment Centers, the CEO and CFO resigned and Kent J. Thiry became CEO in October 1999; the company was renamed DaVita Inc. in October 2000, a name derived from the Italian phrase for 'giving life'. |
| 2005 | DaVita acquired Gambro Healthcare, greatly expanding its U.S. dialysis center network. |
| 2019 | DaVita sold DaVita Medical Group — built around the $4.42 billion 2012 acquisition of HealthCare Partners — to UnitedHealth Group's Optum for $4.3 billion, refocusing the company on kidney care; Javier J. Rodriguez also became CEO in 2019. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $13.64B (FY2025 revenue) |
| Operating income | $2.04B (FY2025 operating income) |
| Net income | $746.8M (FY2025 net income) |
| Diluted EPS | $9.84 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
DaVita is a small-weight Health Care constituent: rank #480 by weight at 0.02% as of Nov 5, 2026, and #55 in Health Care. Its weight understates its real-world footprint: it is one of only two large-scale operators in U.S. dialysis, a recurring, non-discretionary treatment market.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | DaVita Inc. fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $11.94B (Slickcharts, Nov 5, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | DVA |
| 公司 | DaVita Inc.(達維塔) |
| GICS 板塊/行業 | 健康護理(XLV)/醫療護理服務 |
| 標普500排名(按權重) | #480 · 0.02%(Nov 5, 2026) |
| 板塊內排名 | 健康護理板塊 #55(共 60 家)(Nov 5, 2026) |
| 總部 | 美國科羅拉多州丹佛 |
| 成立 | 1979年 |
| 執行長 | Javier J. Rodriguez(行政總裁) |
| 員工 | 約 78,000 名(截至 2025 年 12 月 31 日) |
| 市值 | $11.94B(Nov 5, 2026) |
| SEC 申報 | EDGAR — CIK 927066 |
業務概覽
DaVita Inc. 是美國最大的腎臟護理公司之一。其核心美國透析業務服務慢性腎衰竭及末期腎病(ESKD)患者,這類患者除非接受腎臟移植,通常需每週接受三次透析。截至 2025 年 12 月 31 日,公司在美國營運 2,657 間門診透析中心,服務約 200,500 名患者,並在醫院提供住院透析服務及營運相關臨床實驗室;在美國以外,根據其 Form 10-K 的披露,公司於另外 14 個國家營運透析中心,服務約 94,500 名患者。 DaVita 的收入主要來自醫療保險機構而非患者直接付款。政府計劃主導業務量——2025 年約 89% 的美國患者由政府醫療保險承保,約 68% 的美國透析患者服務收入來自 Medicare 及其他政府計劃——而商業保險機構雖只承保少數患者,但報銷率遠高於政府計劃,貢獻幾乎全部利潤。在此核心之外,其輔助服務分部提供綜合腎臟護理、疾病管理、臨床研究、醫生服務及移植軟件,旨在於腎病較早期階段管理患者。
業務板塊
| 美國透析業務 | 透過 2,657 間美國門診透析中心為慢性腎衰竭及末期腎病患者提供腎臟透析服務,截至 2025 年 12 月 31 日服務約 200,500 名患者,另有醫院住院透析及相關實驗室服務。2025 財年分部總收入為 117.929 億美元,包括 0.610 億美元分部間收入。 |
| 其他——輔助服務 | 輔助及綜合腎臟護理服務,包括國際透析業務、為腎病患者而設的綜合護理及疾病管理計劃、臨床研究、醫生服務及與移植相關的軟件(MedSleuth)。2025 財年分部總收入為 19.223 億美元,包括 0.112 億美元分部間收入。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1979 | 業務以 Medical Ambulatory Care, Inc. 之名創立,是 National Medical Enterprises(現稱 Tenet Healthcare)的附屬公司,DaVita 的歷史即源於此。 |
| 1994 | DLJ Merchant Banking Partners 以 7,550 萬美元槓桿收購公司 70% 股權;公司改名為 Total Renal Care Holdings, Inc.,並於 1995 年 10 月首次公開招股上市。 |
| 1999 | 在 Renal Treatment Centers 的整合困難重重後,行政總裁及財務總裁辭職,Kent J. Thiry 於 1999 年 10 月出任行政總裁;公司於 2000 年 10 月改名為 DaVita Inc.,名字源自意大利語「賦予生命」之意。 |
| 2005 | DaVita 收購 Gambro Healthcare,大幅擴展其美國透析中心網絡。 |
| 2019 | DaVita 以 43 億美元將 DaVita Medical Group(源於 2012 年以 44.2 億美元收購的 HealthCare Partners)出售予 UnitedHealth Group 旗下的 Optum,令公司重新聚焦腎臟護理;Javier J. Rodriguez 亦於 2019 年出任行政總裁。 |
競爭地位
財務快照
| 總收入 | 136.43 億美元(2025 財年收入) |
| 營業利潤 | 20.44 億美元(2025 財年營業利潤) |
| 淨利潤 | 7.47 億美元(2025 財年淨利潤) |
| 稀釋 EPS | 9.84 美元(2025 財年稀釋 EPS) |
主要風險
對標普500的重要性
DaVita 是權重較小的健康護理成分股:截至 2026 年 11 月 5 日,按權重排名第 480 位,權重為 0.02%,在健康護理板塊中排名第 55 位。其權重低估了它的實際影響力:它是美國透析市場僅有的兩家大型營運商之一,而透析是具經常性、非可選性的治療市場。
來源與方法
| 財務、板塊、總部 | DaVita Inc. 2025 財年 Form 10-K(經 SEC EDGAR,見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及 Wikipedia 公司簡介 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $11.94B(Slickcharts,Nov 5, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 14:39 · updated 2026-11-14 23:20 · rev 7